A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET. Company Participants. Stephanie Fagan - Chief Corporate Affairs Officer Rob Bar ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

A groundbreaking trial found vagus nerve stimulation combined with therapy may fully eliminate PTSD symptoms in patients.

Lexeo Therapeutics, Inc.’s LXEO share price has dipped by 12.92%, which has investors questioning if this is right time to ...

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin Desai. Dr. Desai is the founder of Eyestem Research, a biotechnology ...

A very low-carb diet significantly improved the pancreas’s ability to produce insulin in people with mild Type 2 diabetes ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the National Cancer Institute (NCI). | The National Institutes of Health has laid ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.